Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Xacrel (Ocrelizumab) in Relapsing Remitting Multiple Sclerosis
NCT04966338Phase 3Completed
- Sponsor
- CinnaGen
- Start
- Aug 2019
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by CinnaGen. Primary endpoint: Annualized Relapse Rate at 48 weeks. Started Aug 2019; status: completed.
02
Drugs
ocrelizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT04966338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04966338.